Kiadis Pharma’s primary objective is to become a leading biopharmaceutical company focused on developing and commercializing therapeutic products in cell-based immunotherapy. We aim to develop products that provide safer and more efficacious treatment options for cancer and blood disorder patients, improving their survival rate and quality of life.
The information contained on this website does not constitute an offer of securities for sale in the United States, Australia, Canada, Japan, South Africa or any other jurisdiction in which such offers or sales would be unlawful. No securities have been, or will be, registered under the US Securities Act of 1933 or with any securities regulatory authority of any state or other jurisdiction in the United States. No securities may be offered or sold, directly or indirectly, into the United States absent registration or an exemption from registration under the US Securities Act.
Nothing on this website (or any website to which this website has hypertext links) constitutes an invitation or offer to acquire any securities of Kiadis Pharma N.V. or any of its subsidiaries
Media and Investor Contact
Sr. Vice President, Corporate Affairs
Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 (0) 203 950 9144
Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015 under the symbol KDS.
Sep 10 2019Interim results 2019
Apr 13 2018Full Year Results 2017
Aug 25 2017Half Year Results 2017
Mar 31 2017Full Year Results 2016